Un estudio de terapias inhibidoras de guselkumab e interleucina-17 (IL-17) en participantes con artritis psoriásica en la práctica clínica habitual (PsABIOnd)
Evaluación de las terapias con guselkumab (Tremfya) e inhibidores de IL-17 en pacientes con artritis psoriásica en la práctica clínica habitual; Un estudio de cohorte observacional prospectivo
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Psoriatic arthritis (PsA) is a seronegative inflammatory spondylarthritis associated with psoriasis (PsO), which can cause pain and swelling in the joints, sausage-shaped swelling of the fingers and toes (dactylitis), inflammation of the muscle- or tendon insertions at adjacent bone (enthesitis), as well as raised red patches or various other expressions of psoriasis on the skin. Guselkumab (TREMFYA) is a fully human immunoglobulin G1 lambda (IgG1) monoclonal antibody (mAb) that binds to the p19 subunit of human interleukin (IL) 23 with high specificity and affinity, blocking IL-23 binding. Binding of guselkumab to the IL-23p19 subunit blocks the subsequent binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling and subsequent activation and cytokine production. Participants with confirmed diagnosis of PsA who are starting guselkumab or any marketed interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of PsA biologic therapy per standard clinical practice will be enrolled in the main study. The aim of main study is to document the use of guselkumab and approved IL-17i therapies in routine clinical practice in patients with PsA who are starting guselkumab or an IL-17i as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy. The overall duration of the main study, including recruitment and follow-up, is expected to be about 6 years. Participants who are starting guselkumab or an IL-17i treatment per routine clinical practice in the main study, and who meet the selection criteria for both the main study and substudy, will be consecutively offered entry into the substudy (a select number) at the time of enrollment into the main study. The substudy aims to collect additional data, continuously or with increased frequency, on the impact of guselkumab or IL-17i on patient mood, physical activity, sleep disturbance, disease symptoms, and health-related quality-of-life (HRQoL). Total duration of the substudy will be approximately 26-30 weeks consisting of a pre-treatment period of up to 14 days before the first dose of guselkumab or IL-17i in the main study and a 24-week (plus [+] up to 4 weeks follow-up) observation period.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Amberg, Alemania, 92224
- Praxis für Rheumatologie
-
Bayreuth, Alemania, 95444
- Rheuma-Praxis Bayreuth
-
Berlin, Alemania, 12161
- Rheumatologische Schwerpunktpraxis
-
Berlin, Alemania, 13055
- Rheumatologische Schwerpunktpraxis 1
-
Cologne, Alemania, 51149
- Krankenhaus Porz am Rhein
-
Düsseldorf, Alemania, 40225
- Universitatsklinikum Dusseldorf
-
Erfurt, Alemania, 99096
- Service Rheuma Erfurt
-
Frankfurt, Alemania, 60590
- Universitatsklinikum Frankfurt
-
Halle, Alemania, 6128
- Rheumapraxis Dr. Liebhaber
-
Hamburg, Alemania, 22767
- Rheumatologie im Struenseehaus
-
Hamburg, Alemania, 22415
- Praxis fur Klinische Studien und Praxis fur Orthopadie
-
Herne, Alemania, 44649
- Rheumazentrum Ruhrgebiet
-
Leipzig, Alemania, 04109
- Rheumatologische Praxis 1
-
Magdeburg, Alemania, 39104
- Rheumatologische Praxis
-
München, Alemania, 81541
- Praxiszentrum St. Bonifatius
-
Neubrandenburg, Alemania, 17033
- Praxis Thilo Klopsch
-
Püttlingen, Alemania, 66346
- Knappschaftsklinikum Saar GmbH Klinik für Rheumatologie
-
Ratingen, Alemania, 40878
- Rheumazentrum Ratingen
-
Templin, Alemania, 17268
- Rheumatologisch-immunologische Arztpraxis
-
Vogelsang-Gommern, Alemania, 39245
- Immunologisches Zentrum Vogelsang-Gommern GmbH
-
-
-
-
-
Buenos Aires, Argentina, C1199ABB
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentina, C1221ADC
- Hospital J. M. Ramos Mejía
-
Buenos Aires, Argentina, C1015ABO
- OMI
-
Córdoba, Argentina, 5000
- Hospital Cordoba
-
San Fernando, Argentina, B1646
- MR Medicina Reumatologica
-
-
-
-
-
Adelaide, Australia, 5011
- The Queen Elizabeth Hospital
-
Footscray, Australia
- Footscray Hospital, Western Health
-
St Leonards, Australia, 2065
- Royal North Shore Hospital
-
-
-
-
-
Graz, Austria, 8036
- LKH-Univ. Klinikum Graz
-
Linz, Austria, 4021
- Kepler Universitatsklinikum GmbH
-
Vienna, Austria, 1090
- Medizinische Universitaet Wien
-
Vienna, Austria, A-1100
- Evang. Krankenhaus Gemein. Betriebgesm. Mbh
-
-
-
-
-
Bruges, Bélgica, 8000
- AZ Sint-Jan
-
Brussels, Bélgica, 1070
- Hopital Erasme
-
Genk, Bélgica, 3600
- Reumaclinic Genk-Hasselt
-
Leuven, Bélgica, 3000
- UZ Leuven
-
Liège, Bélgica, 4000
- CHU de Liège - Domaine Universitaire du Sart Tilman
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 1J9
- Artus Health Centre
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3A 1M3
- Manitoba Clinic
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canadá, A1C 5B8
- St. Claire's Mercy Hospital - Rheumatology Research
-
-
Nova Scotia
-
Coxheath, Nova Scotia, Canadá, B1L 1B3
- Dr. Juris Lazovskis Incorporated
-
-
Ontario
-
Dundas, Ontario, Canadá, L9H 1B7
- Private Practice - Dr. Pauline Boulos
-
Markham, Ontario, Canadá, L3R 2C7
- Markham Rheumatology Hub
-
Mississauga, Ontario, Canadá, L5A 3V8
- Brandusa Florica Medicine Professional Corporation
-
Orillia, Ontario, Canadá, L3V 1T5
- The Waterside Clinic
-
Ottawa, Ontario, Canadá, K1H 7W9
- The Ottawa Hospital Research Institute
-
Windsor, Ontario, Canadá, N8X 1T3
- Dr Sabeen Anwar Medicine Professional Corporation
-
-
Quebec
-
Montreal, Quebec, Canadá, H1T 2M4
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
-
Québec, Quebec, Canadá, G1V 4K5
- G R M O Groupe de recherche en maladies osseuses Inc
-
Rimouski, Quebec, Canadá, G5L 5T1
- Centre de sante et services sociaux (CSSS) de Rimouski-Neigette - Hopital regional - Rimouski
-
Trois-Rivières, Quebec, Canadá, G9A 3X2
- Centre de Recherche Musculo Squelettique
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7K 0H6
- Community Rheumatology Care
-
Saskatoon, Saskatchewan, Canadá, S7K 0H6
- Rheumatology Associates of Saskatoon
-
-
-
-
-
Bogotá, Colombia
- BIOMAB
-
Bucaramanga, Colombia
- Servimed S A S
-
Medellín, Colombia, 50012
- Clinisalud del Sur
-
Medellín, Colombia, 50025
- Clinica Vascular las Americas
-
Montería, Colombia, 230002
- Funcentra
-
-
-
-
-
Cheonan-si, Corea del Sur, 31151
- Soonchunhyang University Cheonan Hospital
-
Seongnam, Corea del Sur, 13620
- Seoul National University Bundang Hospital
-
Seoul, Corea del Sur, 03080
- Seoul National University Hospital
-
Seoul, Corea del Sur, 07061
- Seoul Metropolitan Government Seoul National University Boramae Medical Center
-
-
-
-
-
A Coruña, España, 15006
- Hosp Univ A Coruna
-
Algeciras / Cadiz, España, 11207
- Hosp. Punta de Europa
-
Barcelona, España, 08036
- Hosp Clinic de Barcelona
-
Barcelona, España, 8035
- Hosp Univ Vall D Hebron
-
Bilbao, España, 48013
- Hosp. Univ. de Basurto
-
Córdoba, España, 14004
- Hosp Reina Sofia
-
Granada, España, 18016
- Complejo hospitalario de Granada
-
Madrid, España, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, España, 28905
- Hosp. Univ. de Getafe
-
Oviedo, España, 33011
- Hosp. Univ. Central de Asturias
-
Santiago de Compostela, España, 15706
- Hosp. Clinico Univ. de Santiago
-
Seville, España, 41013
- Hosp. Virgen Del Rocio
-
-
-
-
-
Bobigny, Francia, 93000
- Hôpital Avicenne
-
Cholet, Francia, 49300
- Centre Hospitalier de Cholet
-
Clermont-Ferrand, Francia, 63003
- Hôpital Gabriel Montpied
-
Créteil, Francia, 94000
- Centre Hospitalier Universitaire(CHU) - Hopital Henri Mondor
-
Lille, Francia, 59037
- CHRU HOPITAL ROGER SALENGRO Consultation Appareil locomoteur
-
Lyon, Francia, 69008
- Centre Orthopedique Santy
-
Lyon, Francia, 69300
- Clinique de l'Infirmerie Protestante de Lyon
-
Nice, Francia, 6006
- Hôpital Saint Roch
-
Orléans, Francia, 45032
- CHR Orléans - Nouvel Hôpital Orléans La Source
-
Paris, Francia, 75018
- Hôpital Bichat
-
Paris, Francia, 75010
- Hôpital Lariboisière - Centre Viggo Petersen
-
Paris, Francia, 75012
- Hopital Saint-Antoine
-
Paris, Francia, 75651
- Hopital Pitie Salpetriere
-
Strasbourg, Francia, 67098
- CHRU Hôpital de Hautepierre
-
Toulouse, Francia, 31059
- Hopital Purpan
-
Échirolles, Francia, 38130
- CHU Grenoble
-
-
-
-
-
Athens, Grecia, 10676
- Evangelismos General Hospital of Athens
-
Athens, Grecia, 11527
- Laiko General Hospital of Athens
-
Athens, Grecia, 11521
- Athens Navy Hospital
-
Athens, Grecia, 11527
- General Hospital 'Gennimatas'
-
Athens, Grecia, 11527
- Hippokration General Hospital of Athens, B' Internal Medicine Clinic,
-
Ioannina, Grecia, 45560
- University Hospital of Ioannina
-
Pátrai, Grecia, 263 32
- 'Agios Andreas' General Hospital of Patras
-
Pátrai, Grecia, 26500
- University General Hospital of Rio Patras
-
Thessaloniki, Grecia, 546 42
- Ippokrateio Hospital
-
-
-
-
-
Bari, Italia, 70124
- Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
-
Campobasso, Italia, 86100
- Ospedale Regionale Cardarelli-Università degli Studi del Mol
-
Catanzaro, Italia, 88100
- Universita della Magna grecia
-
Florence, Italia, 50141
- AOU Careggi
-
Naples, Italia, 80131
- Azienda Ospedaliera Universitaria Federico II
-
Naples, Italia, 80131
- Seconda Univesità degli Studi di Napoli, AOU
-
Palermo, Italia, 90127
- Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
-
Pisa, Italia, 56126
- Azienda Ospedaliero Universitaria Pisana
-
Potenza, Italia, 85100
- Ospedale San Carlo Di Potenza - Azienda Ospedaliera Regionale
-
Rome, Italia, 20123
- Universita Cattolica del Sacro Cuore
-
Rozzano, Italia, 20156
- Istituto Clinico Humanitas
-
Torino, Italia, 10126
- Azienda Ospedaliera Città della Salute e della Scienza di Torino
-
Udine, Italia, 33100
- Azienda Ospedaliero Universitaria S.Maria Della Misericordia
-
Verona, Italia, 37067
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Hyōgo, Japón, 6751392
- Kita-harima Medical Center
-
Meguro-ku, Japón, 153-8515
- Toho University Medical Center, Ohashi Hospital
-
Osaka, Japón, 550 0006
- Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
-
Osaka, Japón, 545 8586
- Osaka Metropolitan University Hospital
-
Sapporo, Japón, 060-8648
- Hokkaido University Hospital
-
Tokyo, Japón, 181 8611
- Kyorin University Hospital
-
-
-
-
-
Mérida, México, 97070
- Medical Care & Research SA de CV
-
México, México, 07760
- Consultorio de Reumatologia
-
Zapopan, México, 45116
- Hospital Puerta de Hierro
-
-
-
-
-
Amsterdam, Países Bajos, 1105 AZ
- Academisch Medisch Centrum Universiteit van Amsterdam
-
Enschede, Países Bajos, 7500 KA
- Medisch Spectrum Twente
-
Groningen, Países Bajos, 9700 RB
- Universitair Medisch Centrum Groningen
-
Helmond, Países Bajos, 5707 HA
- Elkerliek Ziekenhuis
-
-
-
-
-
Aberdeen, Reino Unido, AB25 2ZB
- NHS Grampian - Aberdeen Royal Infirmary (ARI)
-
Abergavenny, Reino Unido, NP7 7EG
- Nevill Hall Hospital
-
Airdrie, Reino Unido, ML6 0JS
- University Hospital Monklands
-
Barnet, Reino Unido, EN5 3DJ
- Royal Free London NHS Foundation Trust Barnet Hospital
-
Bath, Reino Unido, BA1 3NG
- Wolfson Centre Royal United Hospitals
-
Glasgow, Reino Unido, 650029
- Glasgow Royal Infirmary
-
Hull, Reino Unido, HU3 2JZ
- Hull Royal Infirmary
-
Leeds, Reino Unido, LS7 4SA
- Leeds Teaching Hospitals NHS Trust Chapel Allerton Hospital
-
Manchester, Reino Unido, M13 9WL
- Central Manchester University Hospitals NHS Foundation Trust
-
Newcastle upon Tyne, Reino Unido, NE7 7DN
- The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
-
Portsmouth, Reino Unido, PO6 3LY
- Queen Alexandra Hospital
-
Salford, Reino Unido, M6 8HD
- Shirley Caldwell
-
Southampton, Reino Unido, SO16 6YD
- Southampton General Hospital
-
Staffordshire, Reino Unido, ST6 7AG
- Haywood Hospital
-
Stamford, Reino Unido, PE9 1UA
- Stamford and Rutland hospital
-
Wishaw, Reino Unido, ML2 0DP
- Wishaw General
-
-
-
-
-
Kemerovo, Rusia, G4 0SF
- SBEU HPE Kemerovo State Medical Academy
-
Moscow, Rusia, 121552
- Bakoulev Scientific Center For Cardiovascular Surgery Rams
-
Moscow, Rusia, 190068
- FGBU Research Institute of Rheumatology named V.A.Nasonova
-
Tomsk, Rusia, 634045
- City Hospital #3
-
-
-
-
-
Gothenburg, Suecia, 41345
- Sahlgrenska Universitetssjukhuset
-
Malmö, Suecia, 20502
- Universitetssjukhuset i Lund
-
Stockholm, Suecia, 113 65
- Akademiskt Specialistcentrum centrum för reumatologi
-
Uppsala, Suecia, 75185
- Akademiska Sjukhuset
-
Örebro, Suecia, 70185
- Universitetssjukhuset Orebro
-
-
-
-
-
Fribourg, Suiza, 1708
- HFR Fribourg - Hôpital Cantonal
-
-
-
-
-
Kaohsiung City, Taiwán, 81362
- Kaohsiung Veterans General Hospital
-
Kaohsiung City, Taiwán, 83301
- Chang Gung Medical Foundation
-
Taichung, Taiwán
- Taichung Veterans General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study population consists of participants initially treated for Psoriatic Arthritis (PsA) with guselkumab or interleukin-17 inhibitor (IL-17i) per routine clinical practice in accordance with clinical guidelines.
Descripción
Inclusion Criteria:
Main study:
- Have a confirmed diagnosis of PsA as determined by a rheumatologist with reference to Classification criteria for Psoriatic Arthritis (CASPAR)
- Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) at the time of enrollment into the observational study or within a maximum of 2 months after the initial baseline visit or after repeated baseline data collection
- Sign a participation agreement/Informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
- Able to read, understand, and intend to comply with completion of all Electronic patient-reported outcome (ePRO) instruments
- The treatment decision must be taken by the participating rheumatologist prior to, and independently of the participant's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
Substudy:
- Must sign the substudy ICF allowing data collection in accordance with local requirements
- Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in the main study
- Currently using or is willing to use wearables and/or commercial applications to track their disease within the course of their normal daily activities
Exclusion Criteria:
Main study:
- Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment
- Have already taken a specific IL-17i or IL-23i treatment and are planning on re-taking that specific treatment again
- Unwilling or unable to participate in long-term data collection
- Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study (that is, signing of informed consent)
- Currently enrolled in any interventional study or any Janssen-sponsored observational clinical study (contemporary participation into observational studies or registries not sponsored by Janssen is acceptable)
Substudy:
- Have an insufficient command of language to interact effectively with the smartphone application, in the opinion of the investigator at each site
- Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (example, compromise the well-being) or that could prevent, limit, or confound assessment
- Unwilling or unable to comply with substudy assessments
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Cohort 1: Guselkumab
Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study. |
Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
Otros nombres:
|
|
Cohort 2: Interleukin-17 inhibitor (IL-17i)
Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study. |
Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The Start and Stop Date of Guselkumab, as Applicable, For Each Participant
Periodo de tiempo: Up to 39 months
|
The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence. |
Up to 39 months
|
|
The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant
Periodo de tiempo: Up to 39 months
|
The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence. |
Up to 39 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively
Periodo de tiempo: Baseline up to 39 months
|
Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet. |
Baseline up to 39 months
|
|
Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA)
Periodo de tiempo: Baseline up to 39 months
|
The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter [mm]) to "extremely active PsA" (100 mm). |
Baseline up to 39 months
|
|
Change from Baseline in Assessment of Dactylitis
Periodo de tiempo: Baseline up to 39 months
|
The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented. |
Baseline up to 39 months
|
|
Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI)
Periodo de tiempo: Baseline up to 39 months
|
The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right). |
Baseline up to 39 months
|
|
Change from Baseline in Nail Involvement
Periodo de tiempo: Baseline up to 39 months
|
Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes. |
Baseline up to 39 months
|
|
Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement
Periodo de tiempo: Baseline up to 39 months
|
The BSA score indicates the surface area of the participant's body effected by psoriasis. |
Baseline up to 39 months
|
|
Change from Baseline in C-reactive Protein (CRP)
Periodo de tiempo: Baseline up to 39 months
|
Change from baseline in CRP will be reported. |
Baseline up to 39 months
|
|
Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA)
Periodo de tiempo: Baseline up to 39 months
|
Change from Baseline in MDA/VLDA will be reported. |
Baseline up to 39 months
|
|
Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA)
Periodo de tiempo: Baseline up to 39 months
|
DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively. |
Baseline up to 39 months
|
|
Response as a Measure of Clinical Improvement in cDAPSA/DAPSA
Periodo de tiempo: Up to 39 months
|
Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively. |
Up to 39 months
|
|
Start and Stop Dates of All Treatments and the Sequence of Treatment Lines
Periodo de tiempo: Up to 39 months
|
Start and stop dates of all treatments and the sequence of treatment lines will be reported. |
Up to 39 months
|
|
Percentage of Participants with Adverse Events (AEs)
Periodo de tiempo: Up to 39 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 39 months
|
|
BSA PSO Skin Involvement
Periodo de tiempo: Up to 39 months
|
The BSA score indicates the surface area of the participant's body affected by psoriasis. |
Up to 39 months
|
|
Rheumatic Disease Comorbidity Index
Periodo de tiempo: Up to 39 months
|
Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported. |
Up to 39 months
|
|
Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST)
Periodo de tiempo: Baseline up to 6 months
|
FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain. |
Baseline up to 6 months
|
|
Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L)
Periodo de tiempo: Baseline up to 39 months
|
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems. |
Baseline up to 39 months
|
|
Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
Periodo de tiempo: Baseline up to 39 months
|
The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. |
Baseline up to 39 months
|
|
Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12)
Periodo de tiempo: Baseline up to 39 months
|
PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly). |
Baseline up to 39 months
|
|
Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores
Periodo de tiempo: Baseline up to 39 months
|
The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week. |
Baseline up to 39 months
|
|
Change from Baseline in Pain VAS Score
Periodo de tiempo: Baseline up to 39 months
|
The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm). |
Baseline up to 39 months
|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Periodo de tiempo: Baseline up to 39 months
|
BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity. |
Baseline up to 39 months
|
|
Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP)
Periodo de tiempo: Baseline up to 39 months
|
The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value. |
Baseline up to 39 months
|
|
Change from Baseline in Dermatology Life Quality Index (DLQI)
Periodo de tiempo: Baseline up to 39 months
|
The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant. |
Baseline up to 39 months
|
|
Change from Baseline in Patient Acceptable Symptom State (PASS)
Periodo de tiempo: Baseline up to 39 months
|
The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being. |
Baseline up to 39 months
|
|
Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA)
Periodo de tiempo: Baseline up to 39 months
|
The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes. |
Baseline up to 39 months
|
|
Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)
Periodo de tiempo: Baseline up to 39 months
|
TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication. |
Baseline up to 39 months
|
|
Number of Participants Switching or Stopping Treatment
Periodo de tiempo: Up to 39 months
|
Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported. |
Up to 39 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Janssen Pharmaceutica N.V., Belgium Clinical Trial, Janssen Pharmaceutica N.V., Belgium
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades óseas
- Enfermedades musculoesqueléticas
- Artritis
- Enfermedades Articulares
- Enfermedades de la columna
- Espondiloartropatías
- Enfermedades De La Piel Papuloescamosa
- Enfermedades de la piel
- Espondiloartritis
- Espondilitis
- Soriasis
- Enfermedades de la piel y del tejido conectivo
- Artritis, Psoriásica
- guselkumab
Otros números de identificación del estudio
Otros números de identificación del estudio
- CR108938
- CNTO1959PSA4001 (Otro identificador: Janssen Research & Development, LLC)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .